Simvastatin but not ezetimibe reduces sympathetic activity despite similar reductions in cholesterol levels

Journal of the American Society of Hypertension

Volumn 8, Issue 10, 2014, Pages 715-723

  Lewandowski, Jacek ^a   Sinski, Maciej ^a   Puchalska, Liana ^a   Symonides, Bartosz ^a   Gaciong, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Hypercholesterolemia; Microneurography; Statin

Indexed keywords

CHOLESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; AZETIDINE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ADULT; ARTICLE; BLOOD PRESSURE; BORDERLINE HYPERTENSION; CARDIAC PATIENT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HUMAN; HYPERCHOLESTEROLEMIA; IMPEDANCE CARDIOGRAPHY; MALE; MIDDLE AGED; MUSCLE SYMPATHETIC NERVE ACTIVITY; PRESSORECEPTOR; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPATHETIC TONE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR RESISTANCE; ADRENERGIC SYSTEM; BLOOD; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; HEMODYNAMICS; INNERVATION; SKELETAL MUSCLE;

ADULT; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BAROREFLEX; CHOLESTEROL; CHOLESTEROL, HDL; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HEMODYNAMICS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MUSCLE, SKELETAL; SIMVASTATIN; SYMPATHETIC NERVOUS SYSTEM;

EID: 84923251182     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2014.06.003     Document Type: Article

References (38)

1. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reduc-tase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-9.
2. Wassmann S, Laufs U, Baumer AT, Muller K, Konkol C, Sauer H, et al. Inhibition of geranylgerany-lation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 2001;59:646-54.
3. Pliquett RU, Cornish KG, Peuler JD, Zucker IH. Simva-statin normalizes autonomic neural control in experimental heart failure. Circulation 2003;107:2493-8.
4. Pehlivanidis AN, Athyros VG, Demitriadis DS, Papageorgiou AA, Bouloukos VJ, Kontopoulos AG. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 2001; 157:463-9.
5. Hamaad A, Sosin M, Lip GY, MacFadyen RJ. Short-term adjuvant atorvastatin improves frequency domain indices of heart rate variability in stable systolic heart failure. Cardiovasc Drugs Ther 2005;19:183-7.
6. Lewandowski J, Sinski M, Bidiuk J, Abramczyk P, Dobosiewicz A, Ciarka A, et al. Simvastatin reduces sympathetic activity in men with hypertension and hy-percholesterolemia. Hypertens Res 2010;33:1038-43.
7. Gomes ME, Tack CJ, Verheugt FW, Smits P, Lenders JW. Sympathoinhibition by atorvastatin in hypertensive patients. Circ J 2010;74:2622-6.
8. McGowan CL, Murai H, Millar PJ, Notarius CF, Morris BL, Floras JS. Simvastatin reduces sympathetic outflow and augments endothelium-independent dilation in non-hyperlipidaemic primary hypertension. Heart 2013;99:240-6.
9. Sinski M, Lewandowski J, Ciarka A, Bidiuk J, Abramczyk P, Dobosiewicz A, et al. Atorvastatin reduces sympathetic activity and increases baroreceptor reflex sensitivity in patients with hypercholesterolaemia and systemic arterial hypertension. Kardiol Pol 2009; 67:613-20.
10. Kishi T, Hirooka Y, Mukai Y, Shimokawa H, Takeshita A. Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats. J Hypertens 2003;21:379-86.
11. Kishi T, Hirooka Y, Shimokawa H, Takeshita A, Sunagawa K. Atorvastatin reduces oxidative stress in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 2008;30:3-11.
12. Kishi T, Hirooka Y, Konno S, Sunagawa K. Sympa-thoinhibition induced by centrally administered ator-vastatin is associated with alteration of NAD(P)H and Mn superoxide dismutase activity in rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 2010;55:184-90.
13. Gao L, Wang W, Zucker IH. Simvastatin inhibits central sympathetic outflow in heart failure by a nitric-oxide synthase mechanism. J Pharmacol Exp Ther 2008;326:278-85.
14. Kishi T, Hirooka Y, Konno S, Sunagawa K. Atorvasta-tin improves the impaired baroreflex sensitivity via anti-oxidant effect in the rostral ventrolateral medulla of SHRSP. Clin Exp Hypertens 2009;31:698-704.
15. Florian JP, Pawelczyk JA. Non-esterified fatty acids increase arterial pressure via central sympathetic activation in humans. Clin Sci (Lond) 2010;118:61-9.
16. Kalogirou M, Tsimihodimos V, Elisaf M. Pleiotropic effects of ezetimibe: do they really exist? Eur J Pharmacol 2010;633:62-70.
17. Mancia G, Fagard R, Narkiewicz K, Redan J, Zanchetti A, Bohm M, et al. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2013;31:1925-38.
18. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32: 1769-818.
19. Vallbo AB, Hagbarth KE, Torebjork HE, Wallin BG Somatosensory, proprioceptive, and sympathetic activity in human peripheral nerves. Physiol Rev 1979;59: 919-57.
20. Kubicek WG, Karnegis JN, Patterson RP, Witsoe DA, Mattson RH. Development and evaluation of an impedance cardiac output system. Aerosp Med 1966;37: 1208-12.
21. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998;95:8880-5.
22. Kishi T, Hirooka Y, Kimura Y, Ito K, Shimokawa H, Takeshita A. Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. Circulation 2004;109:2357-62.
23. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, et al. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation 2005;112:1763-70.
24. Deo SH, Fisher JP, Vianna LC, Kim A, Chockalingam A, Zimmerman MC, et al. Statin therapy lowers muscle sympathetic nerve activity and oxidative stress in patients with heart failure. Am J Physiol Heart Circ Physiol 2012;303:H377-85.
25. Kurobe H, Aihara K, Higashida M, Hirata Y, Nishiya M, Matsuoka Y, et al. Ezetimibe monotherapy ameliorates vascular function in patients with hyper-cholesterolemia through decreasing oxidative stress. J Atheroscler Thromb 2011;18:1080-9.
26. Kuhlencordt PJ, Padmapriya P, Rutzel S, Schodel J, Hu K, Schafer A, et al. Ezetimibe potently reduces vascular inflammation and arteriosclerosis in eNOS-deficient ApoE ko mice. Atherosclerosis 2009;202:48-57.
27. Patterson D, Dick JB, Struthers AD. Intensive statin treatment improves baroreflex sensitivity: another car-dioprotective mechanism for statins? Heart 2002;88: 415-6.
28. Xie F, Sun C, Sun LH, Li JY, Chen X, Che H, et al. Influence of fluvastatin on cardiac function and baroreflex sensitivity in diabetic rats. Acta Pharmacol Sin 2011; 32:321-8.
29. Moreira ED, Mostarda CT, Moraes-Silva IC, Ferreira JB, Dos Santos F, Lacchini S, et al. Effect of simvastatin in the autonomic system is dependent on the increased gain/sensitivity of the baroreceptors. Physiol Rep 2013;1:e00045.
30. Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, Weissman NJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010;55:2721-6.
31. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43.
32. Briasoulis A, Agarwal V, Valachis A, Messerli FH. Anti-hypertensive effectsofstatins:ameta-analysisofprospec-tive controlled studies. J Clin Hypertens (Greenwich) 2013;15:310-20.
33. Akalin A, Temiz G, Akcar N, Sensoy B. Short term effects of atorvastatin on endothelial functions and oxidized LDL levels in patients with type 2 diabetes. Endocr J 2008;55:861-6.
34. Schneider MP, Schmidt BM, John S, Schmieder RE. Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. J Hy-pertens 2011;29:1757-64.
35. Gounari P, Tousoulis D, Antoniades C, Kampoli AM, Stougiannos P, Papageorgiou N, et al. Rosuvastatin but not ezetimibe improves endothelial function in patients with heart failure, by mechanisms independent of lipid lowering. Int J Cardiol 2010;142: 87-91.
36. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, et al. Simva-statin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005;111:2356-63.
37. Araujo DB, Bertolami MC, Ferreira WP, Abdalla DS, Faludi AA, Nakamura Y, et al. Pleiotropic effects with equivalent low-density lipoprotein cholesterol reduction: comparative study between simvastatin and simvastatin/ezetimibe coadministration. J Cardiovasc Pharmacol 2010;55:1-5.
38. Settergren M, Bohm F, Ryden L, Pernow J. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysgly-caemia and coronary artery disease. Eur Heart J 2008; 29:1753-60.